Literature DB >> 20012235

Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma.

Erkan Dogan, Sercan Aksoy, Cagatay Arslan, Didem S Dede, Kadri Altundag.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20012235     DOI： 10.1007/s12032-009-9378-6

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


× No keyword cloud information.
  7 in total

1.  Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006.

Authors:  Rangaswamy Govindarajan; Josna Adusumilli; Donna L Baxter; Anthony El-Khoueiry; Sami I Harik
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

2.  Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome.

Authors:  E Kapiteijn; A Brand; J Kroep; H Gelderblom
Journal:  Ann Oncol       Date:  2007-10       Impact factor: 32.976

3.  Reversible posterior leukoencephalopathy syndrome and bevacizumab.

Authors:  Cevher Ozcan; Stuart J Wong; Parameswaran Hari
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245

4.  Reversible posterior leukoencephalopathy syndrome induced by sunitinib.

Authors:  German Martín; Lorena Bellido; Juan Jesus Cruz
Journal:  J Clin Oncol       Date:  2007-08-10       Impact factor: 44.544

5.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

6.  A reversible posterior leukoencephalopathy syndrome.

Authors:  J Hinchey; C Chaves; B Appignani; J Breen; L Pao; A Wang; M S Pessin; C Lamy; J L Mas; L R Caplan
Journal:  N Engl J Med       Date:  1996-02-22       Impact factor: 91.245

7.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312
  7 in total
  13 in total

1.  Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancer.

Authors:  Christina A K Kim; Julie Price-Hiller; Quincy S Chu; Keith Tankel; Ron Hennig; Michael B Sawyer; Jennifer L Spratlin
Journal:  Invest New Drugs       Date:  2014-05-23       Impact factor: 3.850

2.  Posterior Reversible Encephalopathy Syndrome in Patients With Cancer.

Authors:  Samuel Singer; Christian Grommes; Anne S Reiner; Marc K Rosenblum; Lisa M DeAngelis
Journal:  Oncologist       Date:  2015-06-01

Review 3.  Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome: Could Hypomagnesaemia Be the Trigger?

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2017-05       Impact factor: 5.606

4.  Sorafenib-induced reversible posterior leukoencephalopathy in patients with renal cell carcinoma: A report of two cases.

Authors:  Nobuki Furubayashi; Takahito Negishi; Hidenori Iwai; Kei Nagase; Motonobu Nakamura
Journal:  Mol Clin Oncol       Date:  2017-06-13

Review 5.  Posterior reversible encephalopathy syndrome induced by anti-VEGF agents.

Authors:  Camille Tlemsani; Olivier Mir; Pascaline Boudou-Rouquette; Olivier Huillard; Karin Maley; Stanislas Ropert; Romain Coriat; François Goldwasser
Journal:  Target Oncol       Date:  2011-11-17       Impact factor: 4.493

6.  Zinc supplementation ameliorates sorafenib-induced cognitive impairment through ROS/JNK signaling pathway.

Authors:  Can-Can Zhou; Yu-Qiong He; Yu-Shuang Qiu; Chen-Xu Ni; Fu-Ming Shen; Dong-Jie Li
Journal:  Biol Trace Elem Res       Date:  2022-02-07       Impact factor: 3.738

7.  Posterior Reversible Encephalopathy Syndrome and Anti-Angiogenic Agents: A Case Report.

Authors:  Filipe Manuel Dos Reis Simões da Silva; Peter Mike Burgos Pêgo; Maria Cristina Henriques Vendrell; Maria João de Azevedo Batalha Ferreira Dos Santos Farias; Ângela Cátia Ribeiro Timóteo; Maria Cristina Martins da Costa; Isabel Maria Monteiro Barbosa Moreira Cravo; Fernando Manuel Ribeiro Gomes
Journal:  Neuroophthalmology       Date:  2011-01-16

8.  Posterior reversible leukoencephalopathy syndrome associated with pazopanib.

Authors:  Robert Foerster; Thomas Welzel; Juergen Debus; Carsten Gruellich; Dirk Jaeger; Karin Potthoff
Journal:  Case Rep Oncol       Date:  2013-04-06

9.  Reversible posterior encephalopathy syndrome secondary to sunitinib.

Authors:  Ricardo Costa; Rubens Costa; Renata Costa; Gilberto Moura de Brito Junior; Henrique Queiroz Cartaxo; Alex Caetano de Barros
Journal:  Case Rep Oncol Med       Date:  2014-05-13

10.  Unexpected side effect in mCRC: A care-compliant case report of regorafenib-induced hyperammonemic encephalopathy.

Authors:  Michela Quirino; Sabrina Rossi; Giovanni Schinzari; Michele Basso; Antonia Strippoli; Alessandra Cassano; Carlo Barone
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.